LONDON, December 5, 2018 /PRNewswire/ --
Global Anti-Obesity Drugs Market Forecast 2018-2028
Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs
(Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1%
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 250-page report you will receive 119 tables and 139 figures- all unavailable elsewhere.
The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Global Anti-obesity Drugs Market forecast from 2018-2028
Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action: Incretion mimetics/GLP-1 agonists SNDRIs Lipase Inhibitors Serotonin receptor agonists Sympathomimetic-GABA receptor agonists Sympathomimetics
Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy: Long-term Drugs Short-term Drugs
Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs: Innovator Generic Drugs
Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC: Prescription Drugs OTC
This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs: Saxenda Contrave/Mysimba Belviq Qysmia Xenical Alli
This report provides individual revenue forecasts from 2018-2028 for these regional and national markets: US Japan EU5: Germany, France, Spain, Italy, UK BRIC: Brazil, Russia, China, India RoW
Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs
Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market: Eisai/Arena GlaxoSmithKline (GSK) Novo Nordisk Orexigen/Takeda Roche Teva Vivus
This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.
This report gives an overview of pricing and reimbursement in the US and EU.
This report provides a SWOT Analysis of the global anti-obesity drugs market.
Visiongain's study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org or refer to our website: https://www.visiongain.com/report/global-anti-obesity-drugs-market-forecast-2018-2028/
Did you know that we also offer a report add-on service? Email email@example.com to discuss any customized research needs you may have.
ADial Pharmaceuticals AEMPS AIFA HAS Akrimax Pharmaceuticals American Medical Association Arena Pharmaceuticals AstraZeneca Biophytis Boehringer Ingelheim Boston Therapeutics Diasome Eisai EMEA Empros Pharma FDA G-BA GenePreDiT GlaxoSmithKline (GSK) Hanmi Ildong Pharmaceuticals Intarcia Therapeutics Ionis Pharmaceuticals Janssen Pharmaceuticals KT&G Life Sciences KVK Tech Kwang Dong Medivation Medlab Clinical Neothetics NGM Biopharmaceuticals NICE SMC Novartis Novo Nordisk OPKO Health Orexigen Rhythm Pharmaceuticals Roche Saniona Shionogi & Co., Ltd Takeda Teva Valeant Pharmaceuticals Virtici Vivus World Health Organization (WHO) Xenetic Biosciences Zafgen
To see a report overview please e-mail Sara Peerun on firstname.lastname@example.org
Subscribe to our Free Newsletters!